
Sight Sciences (SGHT) Stock Forecast & Price Target
Sight Sciences (SGHT) Analyst Ratings
Bulls say
Sight Sciences Inc. is well-positioned for revenue growth, primarily due to anticipated market share gains in the minimally invasive glaucoma surgery (MIGS) sector and accelerated adoption of its TearCare System. The company’s Surgical Glaucoma business is expected to sustain growth in alignment with the overall MIGS market, reinforcing its key revenue drivers. Furthermore, the upward revisions in earnings per share (EPS) projections for 2025 and 2026 indicate improved financial health and progress towards profitability.
Bears say
Sight Sciences Inc. faces a challenging outlook, as it reiterated its 2025 revenue guidance of $72-76 million while anticipating a mid-single-digit percentage decline in third-quarter Surgical Glaucoma revenue year-over-year. The company is further pressured by risks such as increasing competition in minimally invasive glaucoma surgery (MIGS), slow advancements in insurance coverage for its TearCare product, and ongoing concerns about high quarterly cash burn rates. Additionally, while management has adjusted its operational expenditure guidance downward, the reduction may not sufficiently alleviate financial pressures given the external challenges faced by the company.
This aggregate rating is based on analysts' research of Sight Sciences and is not a guaranteed prediction by Public.com or investment advice.
Sight Sciences (SGHT) Analyst Forecast & Price Prediction
Start investing in Sight Sciences (SGHT)
Order type
Buy in
Order amount
Est. shares
0 shares